Compare TG Therapeutics Inc (TGTX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wipro Limited — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Wipro Limited trades at $1.69 (market cap $17.95B). The key difference: Wipro Limited is far larger — about 2.1× TG Therapeutics Inc's market cap, and Wipro Limited pays a 5.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WIT | |
|---|---|---|
Market Cap | $8.53B | $17.95B |
Sector | Health | Technology |
52-Week High | $59.06 | $3.06 |
52-Week Low | $26.94 | $1.68 |
Enterprise Value | $8.74B | $16.02B |
Dividend Yield | — | 5.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
WIT trades at $1.73, down 4.42% today, with bearish technical signals and mixed earnings performance. Recent quarters show earnings misses against expectations, though the company maintains strong profitability with 13.92% net margin and 16.09% ROE. Positive business developments include renewed partnerships with ABB and Databricks to enhance digital and AI services.
The outlook is cautious due to earnings volatility and bearish analyst sentiment, with only 19% buy ratings. Risks include competitive pressures and macroeconomic uncertainty affecting tech spending. The stock's valuation appears reasonable with P/E of 12.98, but investor confidence hinges on improved earnings consistency and margin stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
